Xcout IntelSign inSubscribe

ImmunoScape

BiotechnologySingapore

ImmunoScape is a biotechnology company developing combination cancer therapies, specifically utilizing a novel seed-and-boost approach designed to deliver anti-tumor efficacy at a lower cost. The company serves the biopharmaceutical and oncology healthcare sectors.

Subscribe to see ImmunoScape’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

ImmunoScape at a glance

ImmunoScape is a biotechnology company headquartered in Singapore. Xcout tracks 13 named people at ImmunoScape, including Romi Chandiramani (CHIEF FINANCIAL OFFICER).

Industry
Biotechnology
Headquarters
Singapore

ImmunoScape leadership

  • Romi ChandiramaniCHIEF FINANCIAL OFFICER
  • Choon-Peng NgCHAIRMAN OF THE BOARD
  • Michael FehlingsCHIEF EXECUTIVE OFFICER, CO-FOUNDER
  • Alessandra NardinVP STRATEGY
  • Evan NewellCO-FOUNDER/ADVISOR
  • Andreas WilmVP COMPUTATIONAL BIOLOGY

7 more named people on record for ImmunoScape, with roles, board committees and tenure — see the full roster →

ImmunoScape competitors

A few of ImmunoScape's closest competitors — see the full list of competitors and alternatives →

ImmBiotechUnited States
69% match

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

Valuation—
Employees—
Imm competitors & alternatives →

Get ImmunoScape's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

ImmunoScape — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on ImmunoScape in Xcout Intel

  • 13 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →